Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IVF hartmann Holding AGXSWX:VBSN +1.92%74 ROE % is 13.37% as of Dec. 2025, which is 12% above its 10-year median of 11.96. GuruFocus rates XSWX:VBSN with a GF Score™ of 74/100 and a GF Value™ of CHF143.27 (Fairly Valued). Among 800 Medical Devices & Instruments companies, IVF hartmann Holding AG ranks better than 80.12% on this metric.
The historical rank and industry rank for IVF hartmann Holding AG's ROE % or its related term are showing as below:
XSWX:VBSN'
s ROE % Range Over the Past 10 Years
Min: 4.5 Med: 11.96 Max: 16.88
Current: 12.12
During the past 13 years, IVF hartmann Holding AG's highest ROE % was 16.88%. The lowest was 4.50%. And the median was 11.96%.
XSWX:VBSN's ROE % is ranked better than 80.12% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs XSWX:VBSN: 12.12
IVF hartmann Holding AG (XSWX:VBSN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, IVF hartmann Holding AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IVF hartmann Holding AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IVF hartmann Holding AG's ROE % distribution charts can be found below:
* The bar in red indicates where IVF hartmann Holding AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
IVF hartmann Holding AG (XSWX:VBSN) has a ROE % of 13.37% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on IVF hartmann Holding AG and its competitors. This is 12% above median its historical median of 11.96. Over the past decade, IVF hartmann Holding AG's ROE % has ranged from 4.50 to 16.88. According to the industry distribution chart, IVF hartmann Holding AG ranks #159 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 19.9%.
Is IVF hartmann Holding AG's ROE % too high?
IVF hartmann Holding AG's current ROE % of 13.37% is 12% above median its 10-year median of 11.96. Over the past 10 years, this metric has ranged from a low of 4.50 to a high of 16.88. The Medical Devices & Instruments industry median ROE % is 2.51. IVF hartmann Holding AG's value of 13.37% is 432.7% above this industry median. Based on the distribution chart, IVF hartmann Holding AG ranks #159 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, IVF hartmann Holding AG has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IVF hartmann Holding AG's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, IVF hartmann Holding AG ranks #159 out of 800 companies for ROE %. This places IVF hartmann Holding AG in the top 20% of its industry — outperforming the majority of peers. The industry median ROE % is 2.51. IVF hartmann Holding AG's value of 13.37% is 432.7% above this benchmark. Historically, IVF hartmann Holding AG's own ROE % has ranged from 4.50 to 16.88 over the past decade. While the company's 10-year median is 11.96 vs. the industry median of 2.51, IVF hartmann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.51, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IVF hartmann Holding AG's current ROE % of 13.37% is 432.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on IVF hartmann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IVF hartmann Holding AG's current ROE % is 13.37%, which is 12% above median its own 10-year median of 11.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IVF hartmann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, IVF hartmann Holding AG (XSWX:VBSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF143.27, compared to a current price of CHF132.50 — trading 7.5% below its estimated fair value. The current ROE % is 13.37%, which is 12% above median its 10-year median of 11.96 and 432.7% above the Medical Devices & Instruments industry median of 2.51. IVF hartmann Holding AG's overall GF Score™ is 74/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For IVF hartmann Holding AG (XSWX:VBSN), the current ROE % is 13.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IVF hartmann Holding AG (XSWX:VBSN) Overvalued in 2026?
Based on GuruFocus' analysis, IVF hartmann Holding AG stock appears to be undervalued.
The current stock price of CHF132.50 is trading 7.5% below its estimated GF Value™ of CHF143.27.
GuruFocus considers IVF hartmann Holding AG to be Fairly Valued.
Key valuation signals for XSWX:VBSN:
ROE %: 13.37% (12% above median its 10-year median of 11.96)
GF Value™: CHF143.27 vs. price of CHF132.50 (7.5% below fair value)
Industry Position: 432.7% above the Medical Devices & Instruments median (#159 of 800)
No single metric tells the full story. See the XSWX:VBSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IVF hartmann Holding AG engages in production and supply of medical, pharmaceutical and hygiene products in Switzerland, it offers products such as surgical disposable, disposable dental, first aid, therapeutic plaster, cotton wool, wound care among others. The company operates in four segment wound care, incontinence management, infection management and Other group activities.
74GF Score
Get the complete analysis for XSWX:VBSN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VBSN has been successfully added to your 
